Matarin Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Matarin Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-47,508	Closed	-$2.02M	–	218
2020 Q3	$2.02M	Sell	47,508 -11,469	-19%	-$502K	0.42%	103
2020 Q2	$2.83M	Sell	58,977 -29,296	-33%	-$1.46M	0.56%	82
2020 Q1	$4.06M	Sell	88,273 -81,735	-48%	-$4.1M	0.63%	70
2019 Q4	$10.2M	Sell	170,008 -74,687	-31%	-$4.45M	0.98%	17
2019 Q3	$13.8M	Buy	244,695 +42,043	+21%	+$2.36M	1.05%	13
2019 Q2	$11.3M	Buy	202,652 +73,707	+57%	+$3.84M	0.81%	45
2019 Q1	$6.51M	Sell	128,945 -6,609	-5%	-$294K	0.47%	80
2018 Q4	$5.46M	Buy	135,554 +18,190	+15%	+$937K	0.44%	79
2018 Q3	$8.14M	Buy	117,364 +97,281	+484%	+$7.38M	0.52%	75
2018 Q2	$1.52M	Buy	20,083 +16,128	+408%	+$1.01M	0.11%	183
2018 Q1	$208K	Buy	+3,955	New	+$230K	0.02%	285
2017 Q3	–	Sell	-103,444	Closed	-$8.16M	–	306
2017 Q2	$8.16M	Buy	+103,444	New	+$8.46M	0.76%	45
2016 Q1	–	Sell	-3,221	Closed	-$286K	–	246
2015 Q4	$286K	Buy	+3,221	New	+$254K	0.04%	205

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Matarin Capital Management's EGRX Position: Q4 2020 in Review

Matarin Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 47,508 shares — an estimated $2.02M sold.

Matarin Capital Management first reported a position in EGRX in Q4 2015 and held it in 13 quarters. The position peaked at $13.8M in Q3 2019. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

Matarin Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Matarin Capital Management sold 47,508 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $2.02M.
Matarin Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 13 quarters.
Matarin Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $13.8M in Q3 2019.
166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.